Navigating Endoscopic Surveillance and Management of Barrett's Esophagus in Elderly Patients: Balancing the Risks and Benefits
- PMID: 40488918
- DOI: 10.1007/s11894-025-00984-6
Navigating Endoscopic Surveillance and Management of Barrett's Esophagus in Elderly Patients: Balancing the Risks and Benefits
Abstract
Purpose of review: This review examines the current evidence and practical considerations for endoscopic surveillance of Barrett's esophagus (BE) in elderly patients, focusing on balancing the potential benefits and risks associated with endoscopic surveillance and eradication therapies in this population.
Recent findings: Elderly patients with BE have a higher baseline prevalence of dysplasia and esophageal adenocarcinoma (EAC). Additionally, the risk of progression from BE to EAC increases with advancing age, making surveillance particularly relevant in this population. However, recent studies suggest the benefits of surveillance decline with increasing age, greater comorbidities, and reduced life expectancy. Despite increasing awareness that ongoing surveillance endoscopy may be of minimal benefit for certain patient groups, there remains a paucity of data to guide decisions regarding discontinuation of surveillance. The management of BE in elderly patients requires a careful balance between the potential benefits of endoscopic surveillance and eradication therapies and the risks and costs associated with repeated invasive procedures. Decisions to continue endoscopic surveillance in this population should be individualized, taking into account life-expectancy and comorbidities rather than focusing solely on chronological age.
Keywords: Barrett’s esophagus; Elderly patients; Endoscopic eradication therapy; Endoscopic surveillance; Esophageal adenocarcinoma.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflicts of interest: NJS receives research funding from Lucid Diagnostics, Interpace Diagnostics, Phathom Pharmaceuticals, Medtronic, Steris, Pentax, and CDx Medical and is a consultant for Exact Sciences, Phathom Pharmaceuticals, Cook Medical, Previse, and GIE Medical. All other authors have no personal or financial conflicts of interest to disclose. Grant Support: None.
Similar articles
-
Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma.Gastroenterol Clin North Am. 2022 Sep;51(3):485-500. doi: 10.1016/j.gtc.2022.06.004. Epub 2022 Aug 30. Gastroenterol Clin North Am. 2022. PMID: 36153106 Free PMC article. Review.
-
Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?Dig Dis Sci. 2021 Jun;66(6):1965-1973. doi: 10.1007/s10620-020-06483-0. Epub 2020 Jul 20. Dig Dis Sci. 2021. PMID: 32734400 Free PMC article.
-
Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.Gastroenterology. 2016 Nov;151(5):822-835. doi: 10.1053/j.gastro.2016.09.040. Epub 2016 Oct 1. Gastroenterology. 2016. PMID: 27702561 Review.
-
Screening and surveillance for Barrett's esophagus: current issues and future directions.Curr Opin Gastroenterol. 2012 Jul;28(4):377-81. doi: 10.1097/MOG.0b013e328353d58e. Curr Opin Gastroenterol. 2012. PMID: 22508325 Free PMC article. Review.
-
Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease-Specific Mortality.United European Gastroenterol J. 2025 Mar;13(2):220-228. doi: 10.1002/ueg2.12759. Epub 2025 Feb 13. United European Gastroenterol J. 2025. PMID: 39949075 Free PMC article.
References
-
- Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18:432–43. https://doi.org/10.1038/s41575-021-00419-3 . - DOI - PubMed
-
- Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75. https://doi.org/10.1016/S0140-6736(17)33326-3 . - DOI - PubMed - PMC
-
- Cameron AJ, Lomboy CT. Barrett’s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103:1241–5. https://doi.org/10.1016/0016-5085(92)91510-b . - DOI - PubMed
-
- Guardino JM, Khandwala F, Lopez R, et al. Barrett’s esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol. 2006;101:2187–93. https://doi.org/10.1111/j.1572-0241.2006.00736.x . - DOI - PubMed
-
- Alnasser S, Agnihotram R, Martel M, et al. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus. Can J Surg. 2019;62:93–9. https://doi.org/10.1503/cjs.008716 . - DOI - PubMed - PMC
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials